Search Within

Neha Sanat Korde

Formats
  1. Meeting Abstract (150)
  2. Journal Article (63)
  3. Research Letter (7)
  4. Review (3)
  5. Correspondence (2)
  6. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (226)
  2. Department of Medicine (226)
  3. Hematologic Malignancies, Division of (226)
  4. Myeloma (226)
  5. Survivorship Research (226)
  6. Hematologic Malignancies Research (205)

More Groups

People
  1. Sham Mailankody (181)
  2. Alexander Lesokhin (162)
  3. Hani Hassoun (157)
  4. Malin Hultcrantz (145)
  5. Sergio Giralt (138)
  6. Heather Landau (137)

More People

Years
  1. 2025 (2)
  2. 2024 (36)
  3. 2023 (40)
  4. 2022 (34)
  5. 2021 (15)
  6. 2020 (14)

More Years

Publications
  1. Blood (83)
  2. Clinical Lymphoma, Myeloma and Leukemia (47)
  3. Journal of Clinical Oncology (17)
  4. Leukemia and Lymphoma (11)
  5. Biology of Blood and Marrow Transplantation (7)
  6. Blood Cancer Journal (7)

More Publications

Publishers
  1. American Society of Hematology (89)
  2. Elsevier Inc. (60)
  3. American Society of Clinical Oncology (17)
  4. Nature Publishing Group (13)
  5. Taylor & Francis Group (11)
  6. Ferrata Storti Foundation (7)

More Publishers

Results (226)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy
    Meeting Abstract

    Nath, K.; Shekarkhand, T.; Costa, B. A.; Nemirovsky, D.; Derkach, A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D.; Landau, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating tumor-intrinsic and patient-specific mechanisms of resistance to teclistamab in anti-BCMA exposed and naïve multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I. S.; Wang, A.; Zhu, M.; Patel, D.; Tan, C.; Hultcrantz, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical outcomes associated with del(17p) in newly diagnosed multiple myeloma treated with triplet and daratumumab-based quadruplet induction regimens
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of commercially approved BCMAtargeting CAR-T therapy in triple-class refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Brown, S.; Sean, M. D.; Parastoo, D.; Heather, J. L.; Oscar, B. L.; Michael, S.; Gunjan, L. S.; David, J. C.; Hani, H.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
    Journal Article

    Laracy, J. C.; Yan, J.; Steiger, S. N.; Tan, C. A.; Cohen, N.; Robilotti, E. V.; Fender, J.; Cohen, S.; Korde, N.; Lee-Teh, M.; more...
    Haematologica (2023)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology
    Meeting Abstract

    Maclachlan, K.; Blaney, P.; Gagler, D.; Boyle, E.; Diamond, B.; Shah, U.; Korde, N.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save